Results 31 to 40 of about 7,599 (172)
Poly(ADP-ribose) potentiates ZAP antiviral activity.
PLoS Pathogens, 2022 Zinc-finger antiviral protein (ZAP), also known as poly(ADP-ribose) polymerase 13 (PARP13), is an antiviral factor that selectively targets viral RNA for degradation.
Guangai Xue +10 more
doaj +1 more source
The Current State of the Art in PARP Inhibitor-Based Delivery Nanosystems
Pharmaceutics, 2022 Poly (adenosine diphosphate [ADP]–ribose) polymerases inhibitors (PARPi), the first clinically approved drug that exhibits synthetic lethality, are moving to the forefront of cancer treatments.
Lisha Cai, Xiaoling Xu, Wei Chen
doaj +1 more source
Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer
Biomedicines, 2021 Epithelial ovarian cancer (EOC) is one of the deadliest gynaecological malignancies. The late diagnosis is frequent due to the absence of specific symptomatology and the molecular complexity of the disease, which includes a high angiogenesis potential ...
Maritza P. Garrido +5 more
doaj +1 more source
Indian Journal of Medical and Paediatric Oncology, 2020 Poly(adenosine diphosphate ribose) polymerase inhibitors (PARPis), when used in patients harboring tumor with homologous recombination deficiency, with or without BRCA mutation, have shown favorable outcomes in relapsed, advanced metastatic breast and ...
Avinash Pandey, Joydeep Ghosh
doaj +1 more source
Frontiers in Cell and Developmental Biology, 2022 Homologous recombination DNA repair (HR) is a complex DNA damage repair pathway and an attractive target of inhibition in anti-cancer therapy. To help guide the development of efficient HR inhibitors, it is critical to identify compensatory HR sub ...
Platon Selemenakis +7 more
doaj +1 more source
Therapeutic Advances in Medical Oncology, 2020 Poly[adenosine diphosphate (ADP) ribose]polymerase (PARP) has multifaceted roles in the maintenance of genomic integrity, deoxyribonucleic acid (DNA) repair and replication, and the maintenance of immune-system homeostasis.
Elizabeth K. Lee +1 more
doaj +1 more source
PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
Frontiers in Oncology, 2020 The standard of care for newly diagnosed advanced ovarian cancer (NADOC) is represented by surgical debulking followed by systemic platinum–taxanes combination chemotherapy.
Elisena Franzese +6 more
doaj +1 more source
Prostate cancer and PARP inhibitors: progress and challenges
Journal of Hematology & Oncology, 2021 Despite survival improvements achieved over the last two decades, prostate cancer remains lethal at the metastatic castration-resistant stage (mCRPC) and new therapeutic approaches are needed.
Diego Teyssonneau +8 more
doaj +1 more source
Human autoantibodies to poly(adenosine diphosphate-ribose) polymerase. [PDF]
Journal of Clinical Investigation, 1987 The chromatin-bound enzyme poly(ADP-ribose) polymerase (ADPRP) is strongly stimulated by DNA with single- or double-stranded breaks, and transfers the ADP-ribose moiety of NAD to nuclear proteins. The activation of ADPRP is important for DNA repair and replication, and also has been postulated to play a role in the pathogenesis of lymphocyte ...
H, Yamanaka +5 more
openaire +2 more sources
Advanced Science, EarlyView.This study introduces a biomimetic “nanofusion” platform that integrates the biostability of threose nucleic acids (TNA) with homotypic cell‐membrane cloaking to combat drug‐resistant TNBC. By leveraging a non‐canonical membrane‐fusion pathway for direct cytosolic delivery, the platform bypasses endosomal sequestration. To achieve potent AKT2 silencing
Wei Zheng +7 more
wiley +1 more source